Clinical Trial Update: Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating thalidomide in combination with doxorubicin chemoembolization for unresectable hepatocellular carcinoma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liver Cancer

Drugs mentioned

• Adriamycin (doxorubicin)
• Thalidomide (thalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer | Phase 2 | Status: COMPLETED